ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: After the tremendous success of imatinib therapy in BCR-ABL-positive chronic myelogenous leukemia, imatinib was tried in various myeloproliferative disorders and patients with eosinophilia were found to be particularly sensitive.